Longer PET Acquisition Time Increases FDG-Avid Lymph Node Detection in Rectal Cancer
The procedure also upstaged several subjects.
Longer PET acquisition times during PET/MRI for rectal cancer increases the number of FDG-avid lymph nodes detected without increasing scan time, according to a study published in the American Journal of Roentgenology.
Researchers from the University of California, San Francisco, and the San Francisco VA Medical Center, sought to determine if extended PET acquisition times in the pelvis during PET/MRI increase detection rates of potentially metastatic lymph nodes in patients with rectal cancer.
Twenty-two patients with biopsy-proven rectal cancer participated in the study. All underwent imaging via simultaneous 3-T time-of-flight PET/MRI; seven underwent two separate PET/MRI examinations. This provided a total of 29 studies. Each examination included both a whole-body PET/MRI and a dedicated pelvic PET/MRI with both 3- and 15-minute PET acquisitions for the pelvis. Three radiologists interpreted each examination with PET only, MRI only, then combined PET and MRI examinations, using all available images. Additionally, the 3- and 15-minute PET acquisitions of the pelvis were reviewed separately by a single radiologist.
Related article: PET/MRI Motion Correction Aids in Quantifying, Detecting PET-Avid Lesions
The results showed that 94 lymph nodes were identified as abnormal on PET, all with MRI anatomic correlates. Of these:
- 37 (39.4%) were seen only on the dedicated 15-minute acquisition
- 57 (60.6%) nodes measured 5 mm or less, including 29 (30.9%) seen only on the 15-minute acquisition
- 31 (33.0%) nodes measured 5.1–10 mm, including eight (25.8%) seen only on the 15-minute acquisition
Of the 17 subjects imaged for initial staging, 11 (64.7%) were upstaged as a result of the increased PET acquisition time (10 from N1 to N2 and one from N0 to N1).
The researchers concluded that longer PET acquisition times during PET/MRI for rectal cancer increased the number of FDG-avid lymph nodes detected without increasing scan time.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
FDA Issues Expanded Pediatric Approval of MRI Contrast Agent for Lung Ventilation Assessment
June 2nd 2025Previously approved for MRI lung ventilation evaluation in adults and children 12 and older, the hyperpolarized contrast agent Xenoview can now be utilized for pediatric patients six years and older.
